Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
Press release
Cambridge, MA U.S.A. (September 16, 2022) — Allarity Therapeutics, Inc. (Nasdaq:ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, announced that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1×1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY. Mr. Cullem’s presentation is scheduled for Thursday, September 29, 2022 at 3:00 p.m. ET at the Sofitel Hotel New York at Track 2 – St. Germain III.
Related news for (ALLR)
- Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
- 24/7 Market News Snapshot 22 September, 2025 – Allarity Therapeutics, Inc. Common Stock (NASDAQ:ALLR)
- Biotech Power Hour: Surge Round the Bend
- Power Hour Playbook: Biotech Breakouts, Energy Movers & Niche Innovators to Watch Into the Close
- Breaking News: MoBot’s Latest Update as of 08/26/25 09:00 AM